SEROTONIN NOREPINEPHRINE INHIBITOR MARKET ANALYSIS

Market News

Recent Developments

Acquisition and partnerships

• In 2018, Takeda Pharmaceutical Company, a multinational pharmaceutical company, and Lundbeck, a pharmaceutical company, announced a partnership to co-develop and co-commercialize two new drugs for the treatment of mood disorders, including a serotonin norepinephrine inhibitor.
• In 2020, Eli Lilly, a pharmaceutical company, and Boehringer Ingelheim, a pharmaceutical company, announced a partnership to co-develop and co-commercialize a new drug for the treatment of major depressive disorder, which includes a serotonin norepinephrine inhibitor.
• In 2015, Allergan, a pharmaceutical company and AstraZeneca, a multinational pharmaceutical and biotechnology company, announced a partnership to co-develop and co-commercialize a new drug for the treatment of major depressive disorder, which includes a serotonin norepinephrine inhibitor.